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Synthesis of 3,5-Disubstituted Isoxazoles via 1,3-Dipolar 
Cycloaddition Reaction between Alkynes and Nitrile Oxides 
Generated from O-Silylated Hydroxamic Acids  
Laure-Elie Carloni,[a] Stefan Mohnani,[a]  Davide Bonifazi*[b] 
 
Abstract: In this paper, we report the regioselective synthesis of 3,5-
disubstituted isoxazoles by 1,3-dipolar cycloaddition between alkynyl 
dipolarophiles and nitrile oxide dipoles generated in-situ from O-
silylated hydroxamic acids in the presence of trifluoromethanesulfonic 
anhydride and NEt3. Thanks to the mild, metal-free and oxidant-free 
conditions that this strategy offers, the reaction was successfully 
applied to a wide variety of alkynyl dipolarophiles, demonstrating the 
tolerance of this approach to diverse functional groups. In particular, 
we have shown that the method was compatible with biological 
molecules such as peptides and peptide nucleic acids (PNA). This 
protocol constitutes another example of metal-free 1,3-dipolar 
cycloaddition leading to the regioselective formation of isoxazoles. 
Introduction 
Identified in countless biologically active derivatives, such as 
chlorophyll, amino acids, nucleobases and vitamins, five- and six-
membered heterocycles are of greatest importance to life, drug 
discovery and medicinal chemistry.[1] Among them, isoxazoles 
form a major class of five-membered heterocycles with two 
heteroatoms (Figure 1).[2] Isoxazoles are key pharmacophores 
occurring in many natural products, e.g. ibotenic acid 1 and 
muscimol 2;[3] in a variety of bioactive compounds, such as anti-
inflammatories 3 and 4,[4] monoamine oxidase inhibitor 5,[5] 
penicillin antibiotic 6,[6] and herbicidal isoxaflutole 7.[7] Isoxazoles 
have other biological properties as antitubulin, antinociceptive 
and anticancer.[8] They also find applications in material science, 
e.g. molecular switches and polymer syntheses.[9] Furthermore, 
these heterocycles constitute an important organic synthetic tool. 
Indeed, although isoxazoles are hydrolytically stable, they can be 
cleaved under reducing or basic conditions, leading to different 
important latent functionalities, namely 1,3-dicarbonyl compounds 
8, enaminones 9, and -amino carbonyls 10 (Figure 1).[2, 10] As a 
result, many research groups have used isoxazole derivatives as 
masked functions in synthetic strategies towards heterocyclic 
compounds and natural products.[11] Isoxazoles, and their partially 
saturated analogues, can be prepared using diverse synthetic 
strategies.[12] Among them, the 1,3-dipolar cycloaddition reaction 
between nitrile oxides and corresponding alkenyl and alkynyl 
dipolarophiles is probably the most convenient, attractive and 
direct approach, via a preferred in-situ preparation of the 
dipoles.[1b, 2, 12a, 13] Indeed, as Quilico demonstrated in 1970, nitrile 
oxides in the presence of none or poor trapping agents, readily 
dimerize to furoxans.[14] They can also dimerize to 1,2,4-
oxadiazole 4-oxide in the presence of NEt3.[13a, 13b, 15] 
 
 
Figure 1. Examples of natural products (1-2) and bioactive compounds (3-7) 
bearing an isoxazole function. Isoxazoles can also be used as masked 
functional groups for various synthetic strategies e.g. towards 8-10. 
Several methods towards the in-situ generation of nitrile 
oxides have thus been developed, two of which are by far the 
most popular and well-established protocols. The first approach, 
namely the Mukaiyama method (Figure 2, Method a), involves the 
dehydration of nitroalkanes by aryl isocyanates in the presence of 
NEt3.[13c] The use of POCl3, MeSO2Cl and BzCl as dehydrating 
agents are improved variants of the original Mukaiyama 
procedure.[13a, 13b, 13d, 16] The action of DMAP and Boc2O[17] or 
DMTMM[18] on nitroalkanes was also successfully used to give 
nitrile oxide dipoles. The second method relies on the base-
mediated dehydrochlorination of hydroximoyl chlorides to yield 
the desired nitrile oxides (Figure 2, Method b).[13l] This procedure 
is often carried out as a halogenation/dehydrohalogenation 
reaction on the parent aldoximes, especially for unstable 
hydroximoyl chlorides.[13a, 13b] NCS, tert-BuOCl or NaOCl in the 
presence of NEt3, or chloramine-T without additional bases, are 
frequently employed in these procedures.[13e, 13f] On top of these 
approaches, the direct oxidation of aldoximes through the use of 
MnO2[19] or organic hypervalent iodine reagents[20] is also a 
promising route to the in-situ generation of nitrile oxides (Figure 
2, Method c). Another strategy was described by Carreira and co-
workers in 2000.[21] It involves the treatment of O-silylated 
hydroxamic acids with Tf2O in the presence of NEt3 (Figure 2, 
Method d). In 2019, Dai et al. reported a novel direct Csp3-H bond 
functionalization of 2-methyl ketones and 2-methylquinoline with 
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tert-BuONO, generating nitrile oxide in-situ via a radical 
mechanism (Figure 2, Method e).[22]  
 
 
Figure 2. Overview of the synthetic approaches for preparing nitrile oxides in-
situ: a) dehydration of nitroalkanes; b) dehydrochlorination of hydroximoyl 
chlorides; c) oxidation of aldoximes; d) oxidation of O-silylated hydroxamic 
acids; and e) Csp3-H bond functionalization of 2-methylketones with tert-
BuONO. 
Although the cycloaddition between nitrile oxides and 
alkenyl derivatives is well-developed, the reaction with alkynyl 
dipolarophiles is usually affected by side reactions, often leading 
to byproducts and low yields. This is due to the relatively inert 
character of the triple bond. Following the Cu(I)-catalyzed azide-
alkyne cycloaddition protocol,[23] it was also demonstrated that the 
addition of Cu(I)-[24] or Ru(II)-based[25] catalysts to a mixture of 
alkynes and nitrile oxides, the latter species being generated in-
situ respectively from the parent aldoximes and hydroximoyl 
chloride, led to the formation of 3,5-di or 3,4-di and 3,4,5-
trisubstituted isoxazoles in high yields. Among the metal-free 
protocols, the group of Heaney conjugated aryl moieties with DNA 
on solid phase through a 1,3-dipolar cycloaddition between nitrile 
oxide and alkynyl moieties.[26] In their approach, nitrile oxide was 
generated in-situ by dehydrogenation of aryl aldoxime. In 2011, 
the group of Van Delft described an efficient phenyliodine 
bis(trifluoroacetate) (PIFA)-mediated synthesis of isoxazoles.[20b] 
In a parallel avenue, Kankala et al. reported in 2011 the 
nucleophilic organocarbene-catalyzed 1,3-dipolar cycloaddition 
of nitrile oxides with alkynes.[27] In 2014, the group of Pal reported 
the use of polyethylene glycol to facilitate the 1,3-dipolar 
cycloaddition of benzoylnitromethane and ethyl 2-nitroacetate 
with terminal alkynes leading to isoxazoles under green 
conditions.[28] Recently, the Csp3-H metal-free radical 
functionalization/cycloaddition cascade from ketones, alkynes 
and tert-BuONO proposed by Dai et al. allowed the synthesis of 
3-acyl and 3-quinoline isoxazoles in moderate to good yield.[22]  
While studying metal-free methodologies for the 
bioconjugation of structures of biological interest with functional 
organic dyes,[29] our group became interested in developing an 
alternative bioconjugation approach that would use the 1,3-
dipolar cycloaddition reaction between a nitrile oxide and an 
alkynyl derivative to produce isoxazole linkers. During these 
endeavors, we focused our attention on the Carreira’s protocol,[21] 
that produces isoxazolines via cycloaddition between an alkenyl 
derivative and a nitrile oxide, the latter being produced in-situ from 
O-silylated hydroxamic acids upon treatment with Tf2O and NEt3 
(Figure 2, Method d). In addition to the mild, metal-free and 
oxidant-free conditions that this strategy offers, we conjectured 
that the straightforward preparation of the parent O-silylated 
hydroxamic acids 11R1 could also be easily adapted on a large 
variety of substrates. Indeed, O-silylated hydroxamic acids can be 
readily obtained from the corresponding hydroxamic acids 12R1 
by silylation with tert-butyl(chloro)diphenylsilane in the presence 
of NaH (Scheme 1a). They can also be prepared from the 
corresponding carboxylic acids 13R1 by reaction with O-silylated 
hydroxylamine 14[30] following activation of the carboxylic acid 
moiety with HATU in the presence of DIEA (Scheme 1b). To our 
surprise, this method has not been used to prepare isoxazoles. It 
is with this aim that herein we report the successful adaptation of 
the Carreira’s protocol to the regioselective preparation of 3,5-
disubstituted isoxazoles (Scheme 1c) through the 1,3-dipolar 
cycloaddition reaction between in-situ generated nitrile oxides 
(15R1) and alkynyl dipolarophiles 16R2.  
 
 
Scheme 1. Synthetic protocol proposed in this work: formation of O-silylated 
hydroxamic acids 11R1 a) from hydroxamic acid derivatives 12R1, and b) from 
parent acids 13R1. Yields were 72% and 44% for R1 = Ph, respectively. c) 
Optimized 1,3-dipolar cycloaddition developed in this work for preparing 3,5-
disubstituted isoxazoles 17R1,R2. 
Results and Discussion 
We commenced our studies with the investigation of the basic 
reactivity of alkynes respect to alkenes in the 1,3-dipolar 
cycloaddition reaction with O-silylated hydroxamic acid 11a (R1 = 
Ph). This was achieved using aliphatic compounds 1-octyne 16a 
and 1-octene 18, following Carreira’s procedure (Scheme 2).[21] 
Hence, after dropwise addition of 1 M Tf2O in CH2Cl2 to a solution 
of 11a and NEt3 in CH2Cl2 at -40 °C, the reaction mixture was 
allowed to stir for 1 h at 0 °C, after which an 8-fold excess of 
dipolarophile[31] 16a or 18 was added, and the solution stirred 
overnight at rt. Desired isoxazole 17a and isoxazoline 19 were 
successfully synthesized in 49% and 79% isolated yield, 
respectively. The 30% difference in yield between the two 
reactions confirmed the expected lower reactivity of alkynes.[32]  
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Scheme 2. Evaluation of the reactivity of 1-octyne 16a respect to 1-octene 18 in 
the 1,3-dipolar cycloaddition reaction with nitrile oxide 15a, generated in-situ 
from O-silylated hydroxamic acid 11a. 
Next, we attempted to improve the cycloaddition yield with 
1-octyne 16a.[33] First, all side-products were isolated and 
compared to those obtained in a second trial in which no 
dipolarophile had been added to the reaction mixture. We 
observed that these side-products (Scheme 3, 20/21), of which 
structures 21 were proposed with the support of literature,[13a, 15] 
were identical in the absence and in the presence of 1-octyne. 
This observation suggested that the side-reactions mainly derive 
from nitrile oxide 15a and are independent on the dipolarophile. 
With this information in hand, we attempted the optimization of the 
reaction, with the idea of favoring the intermolecular cycloaddition 
reaction over the other side-reactions. Several conditions were 
explored, mainly focusing on the nitrile oxide generation.[33] 
Parameters such as the excess of the dipolarophile, time, 
temperature, the order of addition of the reagents, as well as the 
concentration of the reaction mixture were studied. Although none 
of these tests gave improved yields, we could conclude that: (i) 
the side-products mainly derived from the reaction of nitrile oxide 
15a with itself or with 20a (Scheme 3); (ii) these side-reactions do 
not take place below 0 °C; and (iii) they are faster than the 1,3-
dipolar cycloaddition with 1-octyne at rt. In light of these 
observations, we decided to monitor the generation of nitrile oxide 
at different temperatures, and noticed that it is formed within three 
minutes at -40 °C. This observation allowed us to improve the 
protocol. Namely, the reaction mixture was allowed to stir only for 
3 min at -40 °C after the addition of Tf2O to a solution of 11a, 
before it was cannulated over 1 h onto neat 1-octyne 16a at rt. 
The solution was then stirred overnight at rt (Scheme 1c). 
Following this procedure, desired isoxazole 17a was formed in 
75% yield, with an overall increase of 26%. To the best of our 
knowledge, this is one of the most efficient synthetic strategies to 
form 5-hexyl-3-phenylisoxazole 17a.[34] Similar yields were 
obtained either using the base-mediated conversion of 
propargylic N-hydroxylamines, through a detosylative 5-endo-dig-
cyclisation,[34a] or exploiting hypervalent iodine to generate in-situ 
the nitrile oxide species.[34b] Having in our hands the optimal 
conditions for our transformation, we extended the protocol to a 
variety of O-silylated hydroxamic acids 11R1 and of alkynyl 
substrates 16R2 (Scheme 4).  
We started by studying the effect of electron withdrawing 
groups (EWG) and electron donating groups (EDG) on the alkynyl 
reagent.[32] Reactions were carried out between O-silylated 
hydroxamic acid 11a and aromatic alkynes: ethynylbenzene 16b 
as a reference, electron-poor 1-ethynyl-4-(trifluoromethyl) 
benzene 16c and electron-rich 4-ethynyl-N,N-dimethylaniline 16d. 
When adding the alkyne in one batch onto benzonitrile oxide 
(according to Scheme 2),[21] both activated dipolarophiles 16c and 
16d gave the corresponding desired isoxazoles in higher yield 
than reference ethynylbenzene 16b (~65% isolated yield respect 
to 54%). 
 
 
Scheme 3. Reaction side-products 20 are formed during the formation of nitrile 
oxide. By-products 21 derive from the dimerization of nitrile oxides. Reported 
structures 21 are proposals which were assigned with the support of 
literature.[13a, 15] 
The cycloaddition reaction yields were increased with 
ethynylbenzene 16b and 1-ethynyl-4-(trifluoromethyl) benzene 
16c by cannulating the nitrile oxide into a solution of the 
dipolarophile (Scheme 1c). Indeed, both dipolarophiles afforded 
desired isoxazoles 17b and 17c in 78% of yield. On the other 
hand, 4-ethynyl-N,N-dimethylaniline 16d seemed to have 
decomposed to some extent under these conditions, thus giving 
an yield of 57%. Although the isolated yield for 3,5-diphenyl 
isoxazole 17b are slightly inferior to the protocols using PIFA 
(90%)[20b] or a mixture of KCl and oxone in H2O (87%),[35] our 
method gave similar results as those obtained with Cu(I)-
catalyzed synthesis of isoxazoles (72%),[24] as well as to other 
metal-based oxidative[19, 20c, 20d, 34b] and dehydrating strategies.[17] 
Using the optimized procedure, we then evaluated the 
compatibility of the reaction conditions with other functional 
groups. The protocol afforded 3-phenyl-5-(trimethylsilyl)isoxazole 
17e in 69% when starting from O-silylated hydroxamic acid 
precursor 11a and ethynyltrimethylsilane 16e. The reaction was 
also successfully applied to ethynylrhodamine 16f (Scheme 5).[36] 
The 1,3-dipolar cycloaddition reaction with nitrile oxide 15a led to 
the formation of desired isoxazole 17f in 66%. Upon formation of 
desired cycloadduct 17f, the ring-opening of the spirolactam 
moiety was observed, as described in Scheme 5.[37] Considering 
its application as molecular sensor, the result obtained with 
rhodamine B 22 was particularly interesting as this strategy offers 
a new route of functionalization of the fluorophore.[38] Indeed, 
modification of the N-terminus of the spiroamide moiety of 16f with 
a conveniently functionalized dipole precursor, could allow its 
conjugation to various receptors for the targets of interests.  
The 1,3-dipolar cycloaddition reaction was tested using 
ethynyltrimethylsilane 16e with polycyclic aromatic dipoles 11b 
and 11c, namely with an anthracenyl and a naphthyl core, 
respectively. The corresponding O-silylated hydroxamic acids 
were synthesized according to Scheme 1b. The desired 
isoxazoles 17g and 17h were respectively generated in 71% and 
67% isolated yields. The 1,3-dipolar cycloaddition reaction was 
also performed between naphthyl precursor 11c and 
ethynylbenzene 16b as well as 4-ethynyl-N,N-dimethylaniline 16d. 
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Corresponding isoxazoles 17i and 17j were formed in 72% and 
61% yield, respectively. 
 
 
Scheme 4. Scope of this work: the optimized protocol for the 1,3-dipolar 
cycloaddition reaction between alkynyl dipolarophiles 16R2 and nitrile oxide 15R1 
generated in-situ from O-silylated hydroxamic acid 11R1 was applied to a variety 
of substrates leading to diverse isoxazoles 17R1,R2. Isolated yields are reported. 
[a] 65% with original Carreira’s protocol. [b] Measured %area of desired 
cycloadduct in the RP-HPLC chromatogram of the crude reaction mixture. [c] 
Calculated from 49% conversion, as determined from the RP-HPLC 
chromatogram of the crude reaction mixture. 
 
Scheme 5. Synthesis of ethynylrhodamine 16f and further 1,3-dipolar 
cycloaddition reaction with nitrile oxide 15a. Upon formation of desired isoxazole 
17f, the ring-opening of the spirolactam form was observed in the presence of 
acid. 
The reaction was also extended to di- and tri-topic 
substrates, starting with the simple di-substitution pattern 
consisting of a 1,4-benzene core. The corresponding O-silylated 
hydroxamic acid 11d was synthesized according to Scheme 1b 
from terephthalic acid in 48% isolated yield, corresponding to 69% 
per functionality. The 1,3-dipolar cycloaddition reaction with 
ethynyltrimethylsilane 16e provided desired 17k in 50% yield, 
corresponding to 71% yield per hydroxamic acid group. Next, we 
focused on a tris-1,3,5-benzene substituted core pattern. O-
silylated hydroxamic acid derivative 11e was synthesized in four 
steps (Scheme 6). First, 4-methoxycarbonylphenylboronic acid 23 
was prepared by esterification of 4-carboxyphenylboronic acid 24 
with MeOH in SOCl2.[39] Reaction with 1,3,5-tribromobenzene 25 
in the presence of a catalytic amount of [Pd(PPh3)4] and Na2CO3 
under microwave conditions,[40] gave desired tricarboxylic acid 
derivative 26 after saponification with aqueous NaOH of resulting 
tris-ester 27.[41] Activation of tris-carboxylic acid 26 with HATU in 
the presence of DIEA, followed by reaction with O-silylated 
hydroxylamine 14, afforded desired nitrile oxide precursor 11e. 
Finally, subsequent cycloaddition reaction with 
ethynyltrimethylsilane 16e provided desired tris-isoxazole 17l in 
39% yield, i.e. 73% yield per functionality. 
 
 
Scheme 6. Synthesis of tris-O-silylated hydroxamic acid precursor 11e and 
subsequent 1,3-dipolar cycloaddition reaction with ethynyltrimethylsilane 16e. 
Lastly, we have studied the cycloaddition reaction between 
O-silylated hydroxamic acid 11a and 1,2-diphenylethyne 16g and 
with 1,4-diethynylbenzene 16h. 3,4,5-triphenylisoxazole 17m was 
obtained in less than 15% yield. This is in line with the limited 
reactivity of internal alkynes with nitrile oxides, as it is well 
established that isoxazoles would exclusively be obtained from 
electron-deficient internal acetylenic dipolarophiles.[2b, 42] On the 
other hand, only one of the two alkynyl moiety of 1,4-
diethynylbenzene 16h was successfully converted to isoxazole, 
leading to derivative 17n in 18% yield. We explained this result by 
considering the constraint imposed by 1,4-diethynylbenzene 16h 
to work with an excess of nitrile oxide, favoring decomposition of 
the latter into by-products over its reaction with alkynyl 
dipolarophile 16h (Scheme 3). 
The 1,3-dipolar cycloaddition reaction was finally used to 
functionalize peptide and peptide nucleic acid (PNA) species. 
Both were synthesized on a solid phase semi-automatic peptide 
synthesizer (Focus XC), using a classical 9-fluorenylmethyl 
carbamate (Fmoc) solid phase procedure (Scheme SI1) on a Rink 
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Amide MBHA resin, with the required amino acids (aa) or PNA 
monomers.[43] A peptide sequence (KFRVGVADVC) displaying 
potential function in antitumor therapies[44] was selected, and 
synthesized (Section 6 in the SI). Functionalization at the N-
terminal position with an acetylenic moiety was subsequently 
achieved to allow the 1,3-dipolar cycloaddition with nitrile oxides 
generated from O-silylated hydroxamic acid 11a (Scheme 7). The 
ethynyl moiety was introduced in the sequence by coupling 5-
hexynoic acid with the relevant peptide precursor 28d under the 
standard solid phase synthesis conditions (Scheme 7a). The 1,3-
dipolar cycloaddition reaction with nitrile oxide 15a was then 
performed on solid phase (Scheme 7b). To this end, a 10-fold 
excess of nitrile oxide, generated in-situ from O-silylated 
hydroxamic acid 11a with Tf2O in the presence of NEt3 at -40 °C, 
was cannulated at the same temperature onto a suspension of 
resin-bound ethynyl-functionalized peptide 16i in DMF, heated at 
50 °C for 16 h. This was followed by cleavage from the resin, 
complete deprotection of the side chains using an acidic cleavage 
mixture TFA/H2O/EDT/TIPS 94:2.5:2.5:1, precipitation with Et2O, 
and analysis of the resulting white solids by reverse phase HPLC 
(RP-HPLC). The RP-HPLC analysis of crude 17o displayed two 
major products, namely isoxazole 17o, and cleaved starting 
material ethynyl-peptide 16i. Incomplete conversion was 
observed likely due to the favored side-reactions of nitrile oxide 
over the reaction with the alkynyl moieties, when the former is in 
excess. Yet, the 1,3-dipolar cycloaddition reaction was shown to 
be compatible with peptidic structures and solid phase synthesis. 
Based on the analytical RP-HPLC chromatogram of the crude 
reaction mixture, 49% conversion of N-terminal ethynyl-peptide 
16i was obtained, of which 41% corresponded to desired 
cycloadded peptide 17o, and 8% to unidentified side-products, 
thereby resulting in 84% yield of peptide-isoxazole conjugate.  
 
Scheme 7. a) Synthesis of resin-bound ethynyl-functionalized peptide 16i; b) 
1,3-dipolar cycloaddition reaction on solid phase between 16i and nitrile oxide 
15a. The yield was calculated based on RP-HPLC chromatogram (%area) of 
the crude reaction mixture and on the measured 49% conversion. PS = 
polystyrene; R1 = amino acid side chain. Sequence: KFRVGVADVC.  
Next, the reaction was attempted on self-complementary 
PNA (sequence: (AATT)3-Lys), which was synthesized from the 
relevant Fmoc/benzyloxycarbonyl (Cbz)-protected PNA 
monomers. Solid phase synthesis, terminal functionalization with 
an acetylenic moiety and reaction with nitrile oxide 15a following 
the same strategies as that described above for ethynyl-peptide 
16i, gave PNA-isoxazole conjugate 17p formed in 43% (yield 
calculated on the %area from the RP-HPLC chromatogram of the 
crude reaction mixture). No trace of ethynyl-functionalized PNA 
16j were detected.[33]  
Conclusions 
In conclusion, we have successfully demonstrated the catalyst- 
and oxidant-free regioselective synthesis of 3,5-disubstituted 
isoxazoles by 1,3-dipolar cycloaddition reactions between alkynyl 
dipolarophiles and nitrile oxides, with the latter reagent being 
produced in-situ under mild conditions. The method is 
experimentally straightforward and convenient as it makes use of 
stable crystalline O-silylated hydroxamic acids dipole precursors 
readily synthesized from the corresponding hydroxamic or 
carboxylic acids. Through the application of the protocol to a 
variety of dipoles and dipolarophiles, we have observed that the 
mildness of this approach provides a tolerance to diverse 
functional groups as different 3,5-disubstituted isoxazoles were 
successfully synthesized in moderate to good yields. In particular, 
we have shown that the method was compatible with biological 
molecules such as peptides and PNA,[45] thus opening the way to 
the biorthogonal applications.[46] An isoxazole derivative of 
rhodamine B was also successfully formed, indicating that the 
strategy could provide a promising new functionalization route 
towards labelling and sensing applications. 
Experimental Section 
General Information: Chemicals were purchased from Sigma Aldrich, 
Acros Organics, Fluorochem, TCI, aapptec, carbosynth, and ABCR, and 
were used as received from the commercial suppliers. Resins for solid 
phase synthesis were purchased from Peptides International and aapptec. 
Solvents were purchased from Sigma Aldrich and Acros Organics. 
Deuterated solvents were purchased from Eurisotop. General solvents 
were distilled in vacuo. Anhydrous CH2Cl2 was distilled from phosphorus 
pentoxide. Anhydrous DMF was purchased from Acros Organics. Low 
temperature baths were prepared using different solvent mixtures 
depending on the desired temperature: -40 °C with CH3CN/liquid N2, -10 
°C with ice/brine, and 0 °C with ice/H2O. Anhydrous conditions were 
achieved by drying Schlenk lines, 2-neck flasks or 3-neck flasks by flaming 
with a heat gun under vacuum and then purging with argon. The inert 
atmosphere was maintained using argon-filled balloons equipped with a 
syringe and needle that was used to penetrate the silicon stoppers used 
to close the flasks’ necks. The addition of liquid reagents was done by 
means of dried plastic syringes or by cannulation, using standard inert 
atmosphere techniques. Microwave reactions were performed on a 
Biotage AB Initiator microwave instrument producing controlled irradiation 
at 2.45 GHz. Solid phase peptide syntheses were performed on a semi-
automatic FOCUS XC peptide synthesizer, coming with a 
computer/control system from aapptec. Reactions were monitored by thin 
layer chromatography (TLC) using pre-coated aluminum sheets with 0.20 
mm Machevery-Nagel Alugram SIL G/UV234 with fluorescent indicator 
UV254 or UV366. Components were visualized by illumination with short-
wavelength UV light. All products were purified by flash column 
chromatography on Grace silica gel 60 (particle size 40-63 µm). Peptide 
and PNA oligomers were analyzed and purified by high performance liquid 
chromatography (HPLC) on a Varian 940-LC liquid chromatograph system 
with a Varian Pursuit C18, 5 µm, 250 × 4.6 mm analytical column and a 
Varian Pursuit C18, 5 µm, 250 × 21.2 mm preparative column. 0.1% TFA 
in H2O and 0.1% TFA in CH3CN were used as eluents in all cases. 
Lyophilisation was performed on a Christ Freeze Dryer ALPHA 2-4 LDplus, 
connected to a Vacuubrand Chemistry-HYBRID-pump, with an ice 
condenser temperature of approx. -85 °C and a vacuum of approx. 2.10-3 
mbar. 1H and 13C NMR spectra were obtained on a 400 MHz NMR (Jeol 
JNM EX-400). Chemical shifts were reported in ppm according to 
tetramethylsilane using the solvent residual signal as an internal reference 
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(CDCl3: H = 7.26 ppm, C = 77.16 ppm; CD2Cl2: H = 5.32 ppm, C = 53.84 
ppm; DMSO-d6: H = 2.50 ppm, C = 39.52 ppm). Coupling constants (J) 
were given in Hz and were averaged. Resonance multiplicity was 
described as s (singlet), d (doublet), t (triplet), q (quartet), quin (quintet), m 
(multiplet), br (broad signal), dd (doublet of doublets). Carbon spectra were 
acquired with a complete decoupling for the proton. 
General Experimental Procedure for the Preparation of O-(tert-
Butyldiphenylsilyl)hydroxamic acids (11) – Hydroxamic acid route 
(Method A): A solution of benzhydroxamic acid (1 eq) in THF was treated 
at 0 °C with NaH (60% in mineral oil, 2 eq) in two portions at 20 min 
intervals, under an inert atmosphere of argon. After 30 min, when all H2 
gas evolution had stopped, the solution was cooled to 0 °C, and tert-
butylchlorodiphenyl silane (1.1 eq) was added dropwise over 30 min. The 
reaction mixture was then allowed to warm up to rt and was stirred for 
additional 2 h. It was subsequently diluted with H2O and extracted with 
EtOAc. The organic extracts were washed with H2O and dried over 
anhydrous Na2SO4, filtered and concentrated to dryness in vacuo. The 
residue was purified by silica gel column chromatography to afford desired 
product 11. With this procedure, we prepared derivative 11a. 
General Experimental Procedure for the Preparation of O-(tert-
Butyldiphenylsilyl)hydroxamic acids (11) – Carboxylic acid route 
(Method B): To a suspension of benzoic acid (1 eq) in anhydrous DMF 
were added DIEA (2 eq) and HATU (1.1 eq), in this order, under an inert 
atmosphere of argon. The resulting reaction mixture was stirred for 30 min 
at rt, after which O-silylated hydroxylamine 14 (1.5 eq) was added at 0 °C 
and the resulting solution stirred overnight (approx. 16 h) at rt. It was then 
concentrated to dryness in vacuo to yield a solid residue, which was 
dissolved in CH2Cl2 and washed with H2O. The aqueous phase was 
extracted with CH2Cl2 and the combined organic phases washed with H2O 
and brine, dried over anhydrous Na2SO4, filtered and concentrated to 
dryness in vacuo. The residue was purified by silica gel column 
chromatography to afford desired product 11. With this procedure, we 
prepared derivatives 11a-e. 
N-((tert-Butyldiphenylsilyl)oxy)benzamide (11a):  
Synthesis according to Method A: Yield 72% (492 mg) of desired product 
11a as a white solid. Synthesis according to Method B: Yield 44% (2.69 g, 
white solid). Rf = 0.42 (Cyclohexane(Cy)/EtOAc 95:5). m.p. 134-137 °C; 
1H NMR (400 MHz, DMSO-d6, *denotes rotamer peaks):  11.40 & 10.92* 
(s, 1H, NH), 7.76 (m, 4H, CH), 7.53-7.37 (m, 11H, CH), 1.11 (s, 9H, CH); 
13C NMR (100 MHz, DMSO-d6):  166.5, 135.5, 132.7, 132.1, 131.4, 130.1, 
128.4, 127.6, 127.2, 26.8, 19.2. All other spectroscopic and analytical 
properties were identical to those reported in the literature.[21]  
N-((tert-Butyldiphenylsilyl)oxy)anthracenyl-9-carboxamide (11b), 
synthesis according to Method B: Yield 41% (351 mg) of desired 
product 11b as a yellow solid. Rf = 0.62 (CH2Cl2/MeOH 95:5). m.p. 91-
94 °C; 1H NMR (400 MHz, DMSO-d6):  11.67 (s, 1H, NH), 8.60 (s, 1H, 
CH), 8.04 (m, 2H, CH), 7.88 (m, 4H, CH), 7.57 (m, 2H, CH), 7.51-7.44 (m, 
6H, CH), 7.30-7.23 (m, 4H, CH) 1.17 (s, 9H, CH), the proton assignment 
has been done by 2D analysis; 13C NMR (100 MHz, DMSO-d6):  165.7, 
135.9, 131.4, 130.4, 130.3, 129.7, 128.2, 127.8, 127.7, 126.4, 125.5, 
125.1, 26.9, 19.2 (one of the quaternary aromatic carbons overlaps with 
another signal); IR (cm–1):  507.3, 698.7, 709.2, 727.8, 737.9, 807.9, 
888.5, 1060.0, 1116.1, 1427.5, 1471.0, 1498.4, 1648.9, 2856.9, 2929.8, 
2955.5, 3052.6, 3200.4; MS (APCI-HR-MS): Found 476.2043 [M+H]+, 
C31H29NO2Si requires = 476.2046.  
N-((tert-Butyldiphenylsilyl)oxy)-1-naphthamide (11c), synthesis 
according to Method B: Yield 48% (237 mg) of desired product 11c as a 
white solid. Rf = 0.45 (Cy/EtOAc 93:7). m.p. 164-167 °C; 1H NMR (400 
MHz, DMSO-d6):  11.48 (s, 1H, NH), 7.95 (m, 1H, CH), 7.89 (m, 1H, CH), 
7.81 (m, 4H, CH), 7.51-7.42 (m, 9H, CH), 7.36-7.34 (m, 1H, CH), 7.27 (d, 
J = 6.9 Hz, 1H, CH), 1.14 (s, 9H, CH), the proton assignment has been 
done by 2D analysis; 13C NMR (100 MHz, DMSO-d6):  166.5, 135.8, 
132.9, 131.9, 131.7, 130.2, 130.1, 129.9, 128.0, 127.6, 126.6, 126.2, 
125.5, 125.1, 124.7, 26.9, 19.2; IR (cm–1):  503.2, 526.6, 567.3, 593.9, 
615.1, 623.3, 689.0, 701.7, 711.6, 734.2, 754.1, 782.6, 805.3, 822.8, 
899.5, 1054.6, 1116.5, 1427.2, 1512.4, 1651.9; MS (ESI-HRMS): 
Found 426.1882 [M+H]+, C27H28NO2Si requires = 426.1884; 
Found 448.1703 [M+Na]+, C27H27NNaO2Si requires = 448.1703.  
N1,N4-bis((tert-Butyldiphenylsilyl)oxy)terephthalamide (11d), 
synthesis according to Method B: Yield 48% (581 mg; 69% per 
functionality) of desired product 11d as a white solid. Rf = 0.51 (Cy/EtOAc 
90:10). m.p. decomposition at 121-123 °C; 1H NMR (400 MHz, DMSO-d6, 
*denotes rotamer peaks):  11.47 & 11.13* (s, 2H, NH), 7.73-7.72 (m, 8H, 
CH), 7.49-7.38 (m, 16H, CH), 1.09 (s, 18H, CH); 13C NMR (100 MHz, 
DMSO-d6):  135.4, 134.6, 132.3, 130.0, 127.6, 126.8, 26.9, 19.2, 
quaternary carbonyl carbon signal was not observed; IR (cm–1):  507.2, 
615.9, 622.7, 697.1, 710.9, 757.7, 764.8, 822.6, 852.8, 894.8, 1013.1, 
1031.2, 1116.0, 1167.2, 1194.4, 1261.1, 1275.7, 1312.3, 1362.1, 1427.7, 
1471.1, 1486.0, 1516.3, 1651.8, 2859.4, 2955.5, 3190.5; MS (ESI-HRMS): 
Found 673.2905 [M+H]+, C40H45N2O4Si2 requires = 673.2912. 
N4,N4''-bis((tert-Butyldiphenylsilyl)oxy)-5'-(4-(((tert-
butyldiphenylsilyl)oxy)carbamoyl)phenyl)-[1,1':3',1''-terphenyl]-4,4''-
dicarboxamide (11e,) synthesis according to Method B: Yield 26% 
(104 mg; 64% per functionality) of desired product 11e as a white solid. Rf 
= 0.39 (CH2Cl2). m.p. 104-107 °C; 1H NMR (400 MHz, DMSO-d6, *denotes 
rotamer peaks):  11.48 & 11.04* (s, 3H, NH), 7.94 (s, 3H, CH), 7.91 (d, J 
= 8.2 Hz, 6H, CH), 7.81-7.74* (m, 13.5H, CH), 7.64* (d, J = 8.2 Hz, 4.5H, 
CH), 7.49-7.40 (m, 18H, CH), 1.13 (s, 27H, CH); 13C NMR (100 MHz, 
DMSO-d6, *denotes rotamer peaks):  166.0, 142.6, 140.7, 135.6, 135.2, 
134.8*, 134.5*, 133.5*, 132.1, 131.8*, 130.1, 129.7*, 129.2*, 127.7, 127.6, 
127.5*, 127.3*, 127.1, 126.2*, 125.1, 27.2*, 26.8, 26.5*, 19.2; IR (cm–1):  
486.8, 502.4, 612.4, 621.6, 649.4, 697.9, 738.7, 760.0, 797.9, 821.9, 
876.7, 909.9, 952.9, 998.3, 1013.8, 1035.5, 1106.78, 1113.9, 1158.7, 
1187.5, 1233.5, 1291.5, 1314.0, 1362.5, 1392.1, 1409.1, 1427.4, 1441.4, 
1371.6, 1487.7, 1526.8, 1588.4, 1609.8, 1681.5, 1899.7, 2857.0, 2893.2, 
2930.3, 3048.8, 3071.8, 3192.4, 3408.3; MS (ESI-HRMS): 
Found 1198.5030 [M+H]+, C75H76N3O6Si3 requires = 1198.5036; Found 
1199.0054 [2M+2H]2+, C150H152N6O12Si6 requires = 1199.0053.  
O-(tert-Butyldiphenylsilyl)hydroxylamine (14): To a stirred suspension 
of hydroxylamine hydrochloride (500 mg, 7.19 mmol) in anhydrous CH2Cl2 
(20 mL) was added NEt3 (1.60 g, 2.21 mL, 15.83 mmol) under an inert 
atmosphere of argon. The mixture was allowed to stir for 1 h at rt. Neat 
tert-butylchlorodiphenyl silane (2.18 g, 2.06 mL, 7.91 mmol) was added, 
and the reaction mixture allowed to stir overnight (approx. 16 h) at rt. The 
mixture was then concentrated to dryness in vacuo and THF (10 mL) 
added to the crude. Triethylamine hydrochloride was removed as a white 
solid by filtration. The flask and precipitate were washed (3 × 5 mL) with 
THF, and the resulting solution concentrated to dryness in vacuo. Ice-cold 
pentane (15 mL) was added to the residue, the mixture briefly sonicated 
and the compound allowed to crystallise in the fridge for 2 h. The solid was 
collected by filtration and washed with ice-cold pentane, yielding 14 (1.77 
g, 91%) as a white crystalline solid. m.p. 68-70 °C; 1H NMR (400 MHz, 
CD2Cl2):  7.75-7.71 (m, 4H, CH), 7.44-7.39 (m, 6H, CH), 1.08 (s, 9H, CH), 
NH protons were not observed; 13C NMR (100 MHz, CD2Cl2):  135.8, 
134.1, 130.0, 128.0, 27.4, 19.4. All other spectroscopic and analytical 
properties were identical to those reported in the literature.[30] 
3',6'-bis(Diethylamino)-2-(prop-2-yn-1-yl)spiro[isoindoline-1,9'-
xanthen]-3-one (16f): To a solution of rhodamine B 22 (1 g, 2.09 mmol) 
in anhydrous 1,2-dichloroethane (82 mL) was added dropwise POCl3 (2.08 
g, 1.26 mL, 13.58 mmol) with vigorous stirring, under an inert atmosphere 
of argon. The mixture was stirred under reflux at 80 °C for 6 h, after which 
it was cooled to rt and concentrated to dryness in vacuo. The resulting 
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residue was dissolved in THF (30 mL) and treated with NEt3 (1.21 g, 1.66 
mL, 12.0 mmol), followed by propargylamine (121 mg, 0.14 mL, 2.2 mmol). 
The solution was stirred overnight (approx. 16 h) at rt, after which it was 
concentrated to dryness in vacuo and subjected to silica gel column 
chromatography (eluent: CH2Cl2) yielding 68% (685 mg) of desired product 
16f as a pale pink solid. Rf = 0.82 (CH2Cl2). m.p. 191-193 °C; 1H NMR (400 
MHz, CDCl3):  7.93-7.90 (m, 1H, CH), 7.44-7.39 (m, 2H, CH), 7.10-7.08 
(m, 1H, CH), 6.46 (d, J = 8.9 Hz, 2H, CH), 6.39 (d, J = 2.5 Hz, 2H, CH), 
6.26 (dd, J1 = 2.5 Hz, J2 = 8.9 Hz, 2H, CH), 3.94 (d, J = 2.5 Hz, 2H, CH), 
3.33 (q, J = 7.1 Hz, CH), 1.75 (t, J = 2.5 Hz, 1H, CH), 1.15 (t, J = 7.1 Hz, 
12H, CH); 13C NMR (100 MHz, CDCl3):  167.4, 153.8, 153.5, 148.8, 
132.6, 130.4, 129.1, 128.0, 123.8, 122.9, 107.9, 105.1, 97.8, 78.3, 70.1, 
64.8, 44.4, 28.5, 12.6. All other spectroscopic and analytical properties 
were identical to those reported in the literature.[36]  
VGVA Acetylenic Peptide (16i): Acetylenic-peptide 16i was synthesised 
on 200 mg scale, following the strategy described on Scheme SI1, using 
the appropriate amino acids. Following synthesis of the desired sequence, 
5-hexynoic acid (68.9 mg, 68 µL, 0.615 mmol) was used in place of an 
amino acid, and a double coupling was achieved in order to ensure a 
quantitative reaction. An aliquot of the resulting crude was isolated, 
cleaved from the resin and analyzed by RP-HPLC. The cleavage cocktail 
mixture used was TFA/H2O/EDT/TIPS 94:2.5:2.5:1. The cleavage took 
place for 4 h, under an inert atmosphere of argon. Peptide 16i was isolated 
as a white solid, soluble in a mixture of H2O/CH3CN 1:1 + 0.1% TFA. HPLC 
retention time: 29.4 min. MS (ESI-HRMS): Found 1186.6520 [M+H]+, 
593.8314 [M+2H]2+, which resolved to 1185.6456  0.0053 [M], 
C54H87N15O13S requires = 1185.6328. Additional synthetic and analytical 
details are described in the supporting information.  
(AATT)3 Lys Acetylenic PNA (16j): Acetylenic PNA dodecamer 16j was 
synthesised on 250 mg scale, following the strategy described on Scheme 
SI1, using the appropriate amino acid (lysine) and PNA monomers. 
Following synthesis of the desired sequence, 5-hexynoic acid (68.9 mg, 
68 µL, 0.615 mmol) was used in place of a PNA monomer, and a double 
coupling was achieved in order to ensure a quantitative reaction. An aliquot 
of the resulting crude was isolated, cleaved from the resin. The Cbz-
protecting groups were deprotected. Resulting deprotected PNA 16j was 
isolated as a white solid, soluble in H2O. HPLC retention time: 11.4 min. 
MS (MALDI-MS): Found 3487.5 [M+H]+, C144H184N69O38 requires = 
3487.46; Found 3509.5 [M+Na]+, C144H183N69NaO38 requires = 3509.44; 
Found 3525.4 [M+K]+, C144H183N69KO38 requires = 3525.42. Additional 
synthetic and analytical details are described in the supporting information.  
General Experimental Procedure for the Preparation of 3,5-
disubstituted Isoxazoles (17) – Method A:[21] To a solution of O-silylated 
hydroxamic acid 11 (1 eq) in anhydrous CH2Cl2 was added NEt3 (3 eq) 
under an inert atmosphere of argon. This was followed by the dropwise 
addition of a 1M solution of Tf2O in CH2Cl2 (1.1 eq) at -40 °C. Once the 
addition was completed, the reaction mixture was allowed to stir for 1 h at 
0 °C, after which alkyne 16 (8 eq) was added, and the resulting mixture 
stirred overnight (approx. 16 h) at rt. Next, the solution was washed with 
H2O. The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated to dryness in vacuo.[3] The residue was purified by silica gel 
column chromatography to afford desired isoxazole 17. With this 
procedure, we prepared cycloadducts 17a-d. 
General Experimental Procedure for the Preparation of 3,5-
disubstituted Isoxazoles (17) – Method B: To a solution of O-silylated 
hydroxamic acid 11 (1 eq) in anhydrous CH2Cl2 was added NEt3 (3 eq) 
under an inert atmosphere of argon. This was followed by the dropwise 
addition of a 1M solution of Tf2O in CH2Cl2 (1.1 eq) at -40 °C. Once the 
addition was completed, the reaction mixture was allowed to stir for 3 min 
at -40 °C, after which it was cannulated batchwise (every 15 min over 45 
min) at that temperature, onto neat alkyne 16 kept at rt (8 eq). The resulting 
mixture was stirred overnight (approx. 16 h) at rt. Next, the solution was 
washed with H2O. The organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated to dryness in vacuo. The residue was purified by 
silica gel column chromatography to afford desired isoxazole 17. With this 
procedure, we prepared cycloadducts 17a-n. 
5-Hexyl-3-phenylisoxazole (17a): Synthesis according to Method A: 
Yield 49% (23 mg) of desired product 17a as a viscous light-yellow oil. 
Synthesis according to Method B: Yield 75% (35 mg, viscous light-yellow 
oil). Rf = 0.58 (CH2Cl2). 1H NMR (400 MHz, CD2Cl2):  7.79-7.76 (m, 2H, 
CH), 7.44-7.42 (m, 3H, CH), 6.31 (s, 1H, CH), 2.77 (m, 2H, CH), 1.74-1.68 
(m, 2H, CH), 1.40-1.29 (m, 6H, CH), 0.89 (t, J = 7.1 Hz, 3H, CH), the proton 
assignment has been done by 2D analysis; 13C NMR (100 MHz, CD2Cl2): 
 174.9, 162.6, 130.1, 129.9, 129.2, 127.1, 99.1, 31.9, 29.2, 27.9, 27.2, 
22.9, 14.2; MS (ESI-HRMS): Found 230.1541 [M+H]+, C15H20NO requires 
= 230.1539. All other spectroscopic and analytical properties were 
identical to those reported in the literature.[34a]  
3,5-Diphenylisoxazole (17b): Synthesis according to Method A: Yield 
54% (16 mg) of desired product 17b as a white solid. Synthesis according 
to Method B: Yield 78% (23 mg, white solid). Rf = 0.58 (CH2Cl2). m.p. 137-
139 °C; 1H NMR (400 MHz, CD2Cl2):  7.85-7.83 (m, 4H, CH), 7.50-7.47 
(m, 6H, CH), 6.88 (s, 1H, CH); 13C NMR (100 MHz, CD2Cl2):  170.7, 
163.3, 130.6, 130.4, 129.6, 129.4, 129.3, 127.8, 127.1, 126.1, 97.9. All 
other spectroscopic and analytical properties were identical to those 
reported in the literature.[20c]  
3-Phenyl-5-(4-(trifluoromethyl)phenyl)isoxazole (17c): Synthesis 
according to Method A: Yield 64% (37 mg) of desired product 17c as a 
white crystalline solid. Synthesis according to Method B: Yield 78% (30 
mg, white crystalline solid). Rf = 0.63 (CH2Cl2). m.p. 172-175 °C; 1H NMR 
(400 MHz, CD2Cl2):  7.97 (d, J = 8.7 Hz, 2H, CH), 7.88-7.85 (m, 2H, CH), 
7.76 (d, J = 8.7 Hz, 2H, CH), 7.50-7.48 (m, 3H, CH), 6.99 (s, 1H, CH); 13C 
NMR (100 MHz, CD2Cl2):  169.2, 163.5, 131.1, 130.6, 129.4, 129.2, 
127.2, 126.6, 126.5, 126.4, 126.3, 99.5. All other spectroscopic and 
analytical properties were identical to those reported in the literature.[12c]  
N,N-Dimethyl-4-(3-phenylisoxazol-5-yl)aniline (17d): 
Synthesis according to Method A: Yield 65% (34 mg) of desired product 
17d as a as a pale yellow solid. Synthesis according to Method B: Yield 
57% (20 mg, pale yellow solid). Rf = 0.52 (CH2Cl2). m.p. 155-158 °C; 1H 
NMR (400 MHz, CD2Cl2):  7.86-7.83 (m, 2H, CH), 7.68 (d, J = 8.9 Hz, 2H, 
CH), 7.47-7.45 (m, 3H, CH), 6.75 (d, J = 8.9 Hz, 2H, CH), 6.64 (s, 1H, CH), 
3.01 (s, 6H, CH); 13C NMR (100 MHz, CD2Cl2):  171.6, 163.1, 152.0, 
130.1, 130.0, 129.2, 127.3, 127.1, 115.4, 112.1, 94.9, 40.3; IR (cm–1):  
689.2, 771.9, 814.4, 926.1, 949.1, 1169.9, 1198.7, 1230.9, 1326.0, 1368.4, 
1397.0, 1413.4, 1446.2, 1466.0, 1507.6, 1524.4, 1578.2, 1614.1, 2922.8; 
MS (ESI-HRMS): Found 265.1334 [M+H]+, C17H17N2O requires = 
265.1335.  
3-Phenyl-5-(trimethylsilyl)isoxazole (17e), synthesis according to 
Method B: Yield 69% (20 mg) of desired product 17e as a pale yellow oil. 
Rf = 0.57 (CH2Cl2). 1H NMR (400 MHz, CD2Cl2):  7.82-7.79 (m, 2H, CH), 
7.47-7.40 (m, 3H, CH), 6.78 (s, 1H, CH), 0.37 (s, 9H, CH); 13C NMR (100 
MHz, CD2Cl2):  179.3, 161.1, 130.1, 129.7, 129.3, 127.3, 111.1, -1.83; IR 
(cm–1):  505.8, 631.1, 684.6, 691.2, 760.2, 839.1, 897.5, 949.4, 971.7, 
1026.5, 1056.2, 1077.9, 1097.9, 1252.2, 1385.1, 1424.1, 1458.9, 1505.2, 
1548.8, 2959.9; MS (ESI-HRMS): Found 218.0995 [M+H]+, C12H16NOSi 
requires = 218.0996. 
3',6'-bis(Diethylamino)-2-((3-phenylisoxazol-5-
yl)methyl)spiro[isoindoline-1,9'-xanthen]-3-one (17f), synthesis 
according to Method B: Yield 66% (53 mg) of desired product 17f as a 
pale pink solid. Rf = 0.17 (CH2Cl2/MeOH 9:1). m.p. 215-217 °C; 1H NMR 
(400 MHz, CD2Cl2):  7.92-7.89 (m, 1H, CH), 7.55-7.53 (m, 2H, CH), 7.49-
7.47 (m, 2H, CH), 7.36-7.35 (m, 3H, CH), 7.07-7.06 (m, 1H, CH), 6.31-6.29 
(m, 4H, CH), 6.14 (m, 2H, CH), 5.80 (s, 1H, CH), 4.41 (s, 2H, CH), 3.20 (q, 
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J = 7.1 Hz, 8H, CH), 1.03 (t, J = 7.1 Hz, 12H, CH), the proton assignment 
has been done by 2D analysis; 13C NMR could not be well acquired due to 
the closed-opened equilibrium of rhodamine’s core, which hampered the 
13C NMR recording of a pure isomer;[37] IR (cm–1):  699.6, 760, 787.3, 
818.1, 920.3, 950, 1018.7, 1089.3, 1118.5, 1152.2, 1219.4, 1265.3, 
1305.1, 1329.3, 1357.3, 1376, 1424.5, 1443.2, 1467.6, 1514.8, 1547.9, 
1614.6, 1634, 1698.3, 2928.5, 2970; MS (ESI-HRMS): Found 599.3008 
[M+H]+, C38H39N4O3 requires = 599.3017; Found 300.1552 [M+2H]2+, 
C38H40N4O3 requires = 300.1545; UV-Vis (CH2Cl2, rt): max [nm] ( [M-1 cm-
1]): 240 (2.1107), 275 (9106), 316 (3.7106). 
3-(Anthracen-9-yl)-5-(trimethylsilyl)isoxazole (17g), synthesis 
according to Method B: Yield 71% (30 mg) of desired product 17g as a 
viscous yellow oil. Rf = 0.51 (CH2Cl2). 1H NMR (400 MHz, CDCl3):  8.57 
(s, 1H, CH), 8.05 (m, 2H, CH), 7.80 (m, 2H, CH), 7.51-7.43 (m, 4H, CH), 
6.69 (s, 1H, CH), 0.48 (s, 9H, CH), the proton assignment has been done 
by 2D analysis; 13C NMR (100 MHz, CDCl3):  178.6, 159.1, 131.3, 130.8, 
128.7, 128.6, 126.4, 125.9, 125.5, 123.7, 116.2, -1.5; IR (cm–1):  622.5, 
734.8, 759.4, 844.8, 1073.0, 1252.8, 1307.2, 1381.3, 1617.4, 1637.8, 
2850.3, 2922.9, 2959.2, 3050.2, 3411.5, 3476.2, 3554.9; MS (APCI-HR-
MS): Found 318.1313 [M+H]+, C20H20NOSi requires = 318.1314. 
3-(Naphthalen-1-yl)-5-(trimethylsilyl)isoxazole (17h), synthesis 
according to Method B: Yield 67% (24 mg) of desired product 17h as a 
viscous colorless oil. Rf = 0.49 (CH2Cl2). 1H NMR (400 MHz, CD2Cl2):  
8.37-8.35 (m, 1H, CH), 7.96-7.91 (m, 2H, CH), 7.70-7.67 (m, 1H, CH), 
7.56-7.52 (m, 3H, CH), 6.77 (s, 1H, CH), 0.42 (s, 9H, CH), the proton 
assignment has been done by 2D analysis; 13C NMR (100 MHz, CD2Cl2): 
 178.4, 161.0, 134.2, 131.5, 130.2, 128.8, 128.1, 127.6, 127.3, 126.6, 
126.1, 125.6, 114.5, -1.76; IR (cm–1):  535.0, 561.6, 630.9, 658.8, 703.3, 
759.8, 773.9, 798.9, 840.2, 887.1, 934.6, 971.8, 1026.7, 1076.0, 1130.3, 
1180.4, 1214.7, 1252.3, 1325.2, 1358.4, 1371.1, 1395.4, 1512.9, 1579.5, 
1597.5, 1730.4, 2900.2, 2959.1, 3050.1; MS (ESI-HRMS): 
Found 268.1153 [M+H]+, C16H18NOSi requires = 268.1152. 
3-(Naphthalen-1-yl)-5-phenylisoxazole (17i), synthesis according to 
Method B: Yield 72% (26 mg) of desired product 17i as a white solid. Rf = 
0.53 (CH2Cl2). m.p. 108-110 °C; 1H NMR (400 MHz, CD2Cl2):  8.45-8.42 
(m, 1H, CH), 7.98 (m, 1H, CH), 7.93 (m, 1H, CH), 7.88 (m, 2H, CH), 7.75 
(m, 1H, CH), 7.59-7.46 (m, 6H, CH), 6.88 (s, 1H, CH), the proton 
assignment has been done by 2D analysis; 13C NMR (100 MHz, CD2Cl2): 
 170.1, 163.5, 134.3, 131.4, 130.7, 130.6, 129.5, 128.9, 128.1, 127.8, 
127.4, 127.3, 126.7, 126.2, 126.0, 125.6, 101.5; IR (cm–1):  535.5, 565.7, 
653.8, 668.1, 687.9, 763.1, 773.7, 797.9, 864.6, 915.7, 936.0, 948.1, 
970.7, 1026.4, 1098.1, 1130.6, 1143.5, 1162.7, 1180.6, 1214.2, 1261.7, 
1292.2, 1335.2, 1364.7, 1378.6, 1408.4, 1446.6, 1475.4, 1497.3, 1514.5, 
1571.5, 1590.6, 1612.4, 1730.7, 1818.8, 1951.1, 2850.8, 2921.6, 3051.9, 
3126.1; MS (ESI-HRMS): Found 272.1068 [M+H]+, C19H14NO requires = 
272.1070. 
N,N-Dimethyl-4-(3-(naphthalen-1-yl)isoxazol-5-yl)aniline (17j), 
synthesis according to Method B: Yield 61% (25.5 mg) of desired 
product 17j as a pale yellow solid. Rf = 0.44 (CH2Cl2). m.p. 122-125 °C; 1H 
NMR (400 MHz, CD2Cl2):  8.47-8.45 (m, 1H, CH), 7.97-7.92 (m, 2H, CH), 
7.75-7.71 (m, 3H, CH), 7.58-7.53 (m, 3H, CH), 6.77 (m, 2H, CH), 6.65 (s, 
1H, CH), 3.02 (s, 6H, CH), the proton assignment has been done by 2D 
analysis; 13C NMR (100 MHz, CD2Cl2):  170.9, 163.3; 152.0, 134.2, 131.5, 
130.3, 128.8, 127.9, 127.8, 127.4, 127.2, 126.6, 126.2, 125.6, 115.4, 
112.2, 98.5, 40.3; IR (cm–1):  659.7, 776.3, 785.4, 803.3, 819.5, 935.7, 
949.9, 1063.1, 1123.3, 1169.0, 1195.8, 1226.9, 1263.7, 1362.5, 1408.4, 
1441.8, 1480.7, 1518.3, 1609.6, 2894.5; MS (ESI-HRMS): 
Found 315.1491 [M+H]+, C21H19N2O requires = 315.1492. 
1,4-bis(5-(Trimethylsilyl)isoxazol-3-yl)benzene (17k), synthesis 
according to Method B: Yield 50% (10.6 mg; 71% per function) of desired 
product 17k as a viscous colorless oil. Rf = 0.54 (CH2Cl2). 1H NMR (400 
MHz, CDCl3):  7.90 (s, 4H, CH), 6.82 (s, 2H, CH), 0.37 (s, 18H, CH); 13C 
NMR (100 MHz, CDCl3):  179.6, 160.5, 130.9, 127.8, 111.1, -1.85; IR (cm–
1):  514.2, 529.8, 608.0, 634.6, 691.7, 706.1, 762.8, 798.1, 822.8, 841.5, 
897.5, 947.7, 971.1, 1021.5, 1063.7, 1101.8, 1217.6, 1251.9, 1276.0, 
1352.4, 1373.6, 1410.6, 1447.2, 1523.0, 1559.4, 2854.1, 2924.8, 2960.4, 
3122.6; MS (ESI-HRMS): Found 357.1451 [M+H]+, C18H25N2O2Si2 
requires = 357.1449. 
3,3'-(5'-(4-(5-(Trimethylsilyl)isoxazol-3-yl)phenyl)-[1,1':3',1''-
terphenyl]-4,4''-diyl)bis(5-(trimethylsilyl)isoxazole) (17l), synthesis 
according to Method B: Yield 39% (38 mg; 73% per functionality) of 
desired product 17l as a white solid. Rf = 0.38 (CH2Cl2). m.p. 42-44 °C; 1H 
NMR (400 MHz, CDCl3):  7.95 (d, J = 8.6 Hz, 6H, CH), 7.93 (s, 3H, CH), 
7.85 (d, J = 8.6 Hz, 6H, CH), 6.84 (s, 3H, CH), 0.39 (s, 27H, CH); 13C NMR 
(100 MHz, CDCl3):  179.5, 160.7, 142.4, 142.1, 129.1, 128.2, 127.9, 
125.7, 111.1, -1.79; IR (cm–1):  505.6, 535.0, 575.2, 609.3, 630.5, 672.2, 
702.0, 736.9, 758.5, 804.9, 836.5, 898.8, 949.7, 971.6, 1018.3, 1050.3, 
1098.9, 1209.0, 1251.8, 1303.2, 1377.2, 1403.2, 1417.9, 1449.6, 1516.8, 
1545.7, 1571.5, 1596.0, 1611.4, 1918.0, 2899.7, 2958.7, 3050.3; MS (ESI-
HRMS): Found 724.2832 [M+H]+, C42H46N3O3Si3 requires = 724.2841; 
Found 362.6461 [M+2H]2+, C42H47N3O3Si3 requires = 362.6457.  
3,4,5-Triphenylisoxazole (17m), synthesis according to Method B: 
Desired derivative 17m was isolated by silica gel column chromatography 
(eluent: CH2Cl2), along with traces of an unidentified by-product. Further 
purification was attempted by means of preparative TLC plates (3 ; 
eluent: CH2Cl2). However, 17m could not be isolated pure. 6 mg of that 
mixture was obtained as a white solid, thus affording less than 15% yield 
in 17m. Rf = 0.69 (CH2Cl2). 1H NMR (400 MHz, CD2Cl2):  8.15 (m, CH), 
7.52-7.44 (m, CH); MS (ESI-HRMS): Found 298.1225 [M+H]+, C21H16NO 
requires = 298.1226.  
5-(4-Ethynylphenyl)-3-phenylisoxazole (17n), synthesis according to 
Method B: Yield 18% (7 mg) of product 17n as a white solid. Rf = 0.58 
(CH2Cl2). m.p. 96-98 °C; 1H NMR (400 MHz, CD2Cl2):  7.86-7.84 (m, 2H, 
CH), 7.80 (d, J = 8.6 Hz, 2H, CH), 7.60 (d, J = 8.6 Hz, 2H, CH), 7.49-7.47 
(m, 3H, CH), 6.90 (s, 1H, CH), 3.26 (s, 1H, CH); 13C NMR (100 MHz, 
CD2Cl2):  169.8, 163.4, 133.1, 130.5, 129.3, 129.1, 127.9, 127.1, 126.0, 
124.3, 98.7, 83.2, 79.5; IR (cm–1):  511.4, 543.2, 615.2, 627.1, 663.7, 
692.7, 764.0, 819.0, 845.3, 916.6, 949.9, 1044.9, 1090.1, 1112.1, 1399.2, 
1413.7, 1462.4, 1493.7, 2920.0, 3298.2; MS (ESI-HRMS): 
Found 246.0914 [M+H]+, C17H12NO requires = 246.0913. 
VGVA Peptide-isoxazole conjugate (17o): To a solution of O-silylated 
hydroxamic acid of phenyl 11a (180 mg, 0.48 mmol) in anhydrous CH2Cl2 
(7.2 mL) was added NEt3 (146 mg, 202 µL, 1.44 mmol) under an inert 
atmosphere of argon. This was followed by the dropwise addition of a 1 M 
solution of Tf2O in CH2Cl2 (528 µL, 0.528 mmol) at -40 °C. Once the 
addition was completed, the reaction mixture was allowed to stir for 3 min 
at -40 °C, after which it was added to a suspension of resin-bound ethynyl-
functionalized peptide 16i (100 mg, 0.048 mmol) in DMF (2 mL). The 
resulting mixture was shaken overnight (approx. 16 h) at 50 °C. The 
solution was then filtered and washed with DMF (5 × 5 mL) and CH2Cl2 (7 
× 5 mL). The resulting crude was isolated, cleaved from the resin, analyzed 
and purified by RP-HPLC. The cleavage cocktail mixture used was 
TFA/H2O/EDT/TIPS 94:2.5:2.5:1. The cleavage took place for 4 h, under 
an inert atmosphere of argon. Peptide 17o was isolated as a white solid, 
soluble in a mixture of H2O/CH3CN 1:1 + 0.1% TFA. HPLC retention time: 
26.7 min. MS (MALDI-HRMS): Found 1305.6781 [M+H]+, C61H93N16O14S 
requires = 1305.6778; Found 1327.7 [M+Na]+, C61H92N16NaO14S requires 
= 1327.66; Found 1343.6 [M+K]+, C61H92N16KO14S requires = 1343.63. 
Based on the analytical RP-HPLC chromatogram, it was calculated that 
49% conversion was obtained, of which 41% corresponded to desired 
cycloadded peptide 17o, and 8% to unidentified subproducts. 51% of 
starting acetylenic-peptide 16i were recovered thereby resulting in 84% 
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yield of peptide-isoxazole conjugate. Percentages are given as area%. 
Additional synthetic and analytical details are described in the supporting 
information. 
(AATT)3 Lys PNA-isoxazole conjugate (17p): To a solution of O-silylated 
hydroxamic acid of phenyl 11a (19 mg, 0.040 mmol) in anhydrous CH2Cl2 
(50 µL) was added NEt3 (12.2 mg, 16.6 μL, 0.12 mmol) under an inert 
atmosphere of argon. This was followed by the dropwise addition of a 1 M 
solution of Tf2O in CH2Cl2 (44 µL, 0.044 mmol) at -40 °C. Once the addition 
was completed, the reaction mixture was allowed to stir for 3 min at -40 
°C, after which it was added to a suspension of resin-bound Cbz-protected 
ethynyl-functionalized PNA 16j (10 mg, 0.0041 mmol) in DMF (200 µL). 
The resulting mixture was shaken overnight (approx. 16 h) at 50 °C. The 
solution was then filtered and washed with DMF (5 × 5 mL) and CH2Cl2 (7 
× 5 mL). The resulting crude was isolated, cleaved from the resin and the 
Cbz groups deprotected. Resulting deprotected PNA 17p was analyzed 
and purified. PNA 17p was isolated as a white solid, soluble in a mixture 
of H2O/CH3CN 1:1 + 0.1% TFA. HPLC retention time: 18.1 min. MS 
(MALDI-HRMS): Found 3606.6648 [M+H]+, C151H189N70O39 requires = 
3606.4952; Found 3628.6714 [M+Na]+, C151H188N70NaO39 requires = 
3628.4772; Found 3644.6257 [M+K]+, C151H188N70KO39 requires = 
3644.4511. 17p was formed in 43% (%area of desired cycloadduct in the 
RP-HPLC chromatogram). Additional synthetic and analytical details are 
described in the supporting information. 
5-Hexyl-3-phenyl-4,5-dihydroisoxazole (19): To a solution of O-silylated 
hydroxamic acid of phenyl 11a (75 mg, 0.2 mmol) in anhydrous CH2Cl2 (3 
mL) was added NEt3 (60.7 mg, 83.6 µL, 0.6 mmol) under an inert 
atmosphere of argon. This was followed by the dropwise addition of a 1M 
solution of Tf2O in CH2Cl2 (220 µL, 0.22 mmol) at -40 °C. Once the addition 
was completed, the reaction mixture was allowed to stir for 1 h at 0 °C, 
after which 1-octene 18 (179.6 mg, 252 µL, 1.6 mmol) was added, and the 
resulting mixture stirred overnight (approx. 16 h) at rt. Next, the solution 
was washed with H2O (2 × 1 mL). The organic layer was dried over 
anhydrous Na2SO4, filtered and concentrated to dryness in vacuo. The 
residue was purified by silica gel column chromatography (eluent: CH2Cl2), 
yielding 19 (36.6 mg, 79%) as a white solid. Rf = 0.56 (CH2Cl2). m.p. 49-
52 °C; 1H NMR (400 MHz, CD2Cl2, *denotes rotamer peaks):  7.65-7.62 
(m, 2H, CH), 7.39-7.37 (m, 3H, CH), 4.67-4.65 (m, 1H, CH), 3.40-3.33 & 
2.97-2.90* (m, 2H, CH), 1.78-1.70 & 1.62-1.55* (m, 2H, CH), 1.47-1.24 (m, 
8H, CH), 0.89-0.85 (t, J = 7.0 Hz, 3H, CH), the proton assignment has 
been done by 2D analysis; 13C NMR (100 MHz, CD2Cl2):  156.7, 130.5, 
130.1, 129.0, 126.8, 81.9, 40.2, 35.7, 32.1, 29.5, 25.9, 22.9, 14.2. All other 
spectroscopic and analytical properties were identical to those reported in 
the literature.[20c]  
 (4-(Methoxycarbonyl)phenyl)boronic acid (23): To a solution of 4-
carboxyphenyl boronic acid 24 (1 g, 6.03 mmol) in anhydrous MeOH (17.4 
g, 22 mL, 543 mmol) was slowly added SOCl2 (4.5 g, 2.7 mL, 37.39 mmol) 
under an inert atmosphere of argon. The resulting mixture was stirred for 
2 h 30 at 50 °C, after which it was concentrated to dryness in vacuo. The 
compound was also dried under high vacuum to remove any residual trace 
SOCl2. The residue was dissolved in EtOAc (50 mL) and washed with brine 
(20 mL). The aqueous phase was extracted with EtOAc (2 × 30 mL) and 
the combined organic phases dried over anhydrous MgSO4, filtered and 
concentrated to dryness in vacuo to yield 23 as a white solid (1 g, 92%). 
No further purification was required. m.p. 232-233 °C; 1H NMR (400 MHz, 
CDCl3):  8.29 (d, J = 8.0 Hz, 2H, CH), 8.17 (d, J = 8.0 Hz, 2H, CH), 3.98 
(s, 3H, CH), BOH proton signals were not observed; 13C NMR (100 MHz, 
CDCl3):  167.1, 135.7, 134.0, 133.6, 129.1, 52.5. All other spectroscopic 
and analytical properties were identical to those reported in the literature.[39, 
47]  
5'-(4-Carboxyphenyl)-[1,1':3',1''-terphenyl]-4,4''-dicarboxylic acid 
(26): Tri-ester 27 (370 mg, 0.77 mmol) was dissolved in a mixture of 
THF/MeOH 1:1 (14 mL), and 7 mL of 4.8 M aq. solution of NaOH (1.344 g, 
33.6 mmol) added at 0 °C. The reaction mixture was stirred overnight 
(approx. 16 h) at rt, after which the solvents were evaporated in vacuo. 
The residue was solubilised in H2O (minimum amount, i.e. 7 mL) and the 
resulting solution acidified to pH ~2 with 1 M aq. solution of HCl. The 
resulting white precipitate was filtered, collected, resuspended in H2O (5 
mL), sonicated and filtered once more. Through this procedure, NaCl salts 
were washed out. The white solid was collected and dried under high 
vacuum (233 mg, 70% yield in 26). m.p. 316-319 °C; 1H NMR (400 MHz, 
DMSO-d6):  8.09 (s, 3H, CH), 8.06 (s, 12H, CH), COOH proton signals 
were not observed; 13C NMR (100 MHz, DMSO-d6):  167.1, 143.8, 140.8, 
130.0, 129.9, 127.4, 125.6. All other spectroscopic and analytical 
properties were identical to those reported in the literature.[41, 48]  
Dimethyl 5'-(4-(methoxycarbonyl)phenyl)-[1,1':3',1''-terphenyl]-4,4''-
dicarboxylate (27): Na2CO3 (1.01 g, 9.53 mmol), 4-
methoxycarbonylphenylboronic acid 23 (1.28 g, 7.15 mmol), 1,3,5-
tribromobenzene 25 (500 mg, 1.59 mmol) and [Pd(PPh3)4] (184 mg, 0.159 
mmol) were weighed into a 10-20 mL microwave flask, under an inert 
atmosphere of argon. A degassed mixture of toluene/EtOH 1:1 (17 mL) 
was then added to the solids (Note: toluene and EtOH are degassed in two 
different two-neck flasks; simple argon bubbling (with two argon balloons 
and two thick needle outlets), for 45 min is enough to degas the solvents 
for this reaction; drops of water are added in EtOH). The resulting mixture 
was stirred for 5 min before being heated at 110 °C for 4 h under 
microwave conditions (the pressure rose up to 8 bars). The solution was 
then diluted with CH2Cl2 (250 mL) and extracted with H2O (3 × 100 mL) 
and brine (1 × 100 mL). The organic phase was dried over anhydrous 
MgSO4, filtered and concentrated to dryness in vacuo. The residue was 
purified by silica gel column chromatography (eluent: Cy to Cy/EtOAc 4:6) 
yielding 48% of desired product 27 (370 mg) as a white solid. Rf = 0.45 
(Cy/EtOAc 4:6). 1H NMR (400 MHz, CDCl3):  8.16 (d, J = 8.2 Hz, 6H, CH), 
7.86 (s, 3H, CH), 7.77 (d, J = 8.5 Hz, 6H, CH), 3.96 (s, 9H, CH).[40, 49] The 
next step, i.e. saponification, was performed on the whole batch, without 
further characterizations of tri-ester derivative 27. 
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